🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Longboard Pharmaceuticals concludes merger with H. Lundbeck A/S

EditorEmilio Ghigini
Published 12/02/2024, 10:20 PM
LBPH
-

In a significant corporate development, Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) has finalized its acquisition by H. Lundbeck A/S, a Danish pharmaceutical firm, as of Monday. This transaction follows the Merger Agreement dated October 14, 2024, and the successful tender offer of $60.00 per share for Longboard's common stock.

The acquisition price represents a remarkable premium, as shown by InvestingPro data indicating a staggering 1,399% return over the past year, with the stock trading near its 52-week high of $60.03.

The acquisition led to the termination of Longboard's 2020 and 2021 Equity Incentive Plans and its 2021 Employee Stock Purchase Plan. Longboard's common stock, which maintained strong financial health with a current ratio of 15.97 according to InvestingPro data, has been delisted from the Nasdaq Global Market as of Monday, following the transfer of ownership.

Stock options and restricted stock units (RSUs) held by Longboard employees were converted to the right to receive cash equal to the difference between the merger consideration and the exercise price for each share. Longboard has become a wholly owned subsidiary of H. Lundbeck A/S, and all previous directors and officers have resigned, with the directors and officers of the acquiring subsidiary stepping into their roles.

The merger has resulted in significant changes in the rights of Longboard's security holders, as all outstanding shares have been converted to the right to receive the offer price in cash. The completion of this acquisition marks a change in control of the registrant, with Longboard now operating under the full ownership of its parent company, H. Lundbeck A/S.

The Company's certificate of incorporation and bylaws were also amended and restated to reflect the new corporate structure. This news is based on a press release statement and provides key insights for investors regarding the recent changes in Longboard Pharmaceuticals' corporate governance and ownership.

For detailed analysis of similar pharmaceutical companies and their financial metrics, investors can access comprehensive Pro Research Reports available on InvestingPro, covering over 1,400 US-listed companies.

In other recent news, Longboard Pharmaceuticals has been the focus of several significant developments. The company has been downgraded from Buy to Neutral by a B.Riley analyst, despite a price target increase to $60 from $45, following the announcement of a $2.6 billion acquisition by Lundbeck. This acquisition, unanimously approved by the boards of both companies, is expected to finalize in the fourth quarter of this year.

Longboard's lead asset, bexicaserin, which is currently in phase III trials, has received Breakthrough Therapy Designation from the U.S. FDA. The company has also initiated a global Phase 3 clinical trial for bexicaserin, a treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).

Lundbeck's acquisition of Longboard is seen as a strategic move, especially considering the promising data generated by Longboard and its potential for market expansion. Analyst firms, including H.C. Wainwright, Baird, and Truist Securities, have expressed confidence in Longboard's growth prospects, maintaining positive ratings for the company. These recent developments highlight the ongoing efforts of Lundbeck and Longboard to address the significant unmet needs in epilepsy treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.